<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296240</url>
  </required_header>
  <id_info>
    <org_study_id>PKUCH-R03</org_study_id>
    <nct_id>NCT04296240</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer</brief_title>
  <official_title>Safety and Efficacy of Induction and Individualized Neoadjuvant Chemotherapy Based on Oxaliplatin Combined With Fluorouracil for MRF-negative, Moderate-risk and Initially Resectable Middle and Low Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test the Safety and efficacy of induction and individualized&#xD;
      neoadjuvant chemotherapy based on oxaliplatin combined with fluorouracil for MRF-negative,&#xD;
      moderate-risk and initially resectable middle and low rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperative chemoradiation has become standard treatment for stage 2/3 rectal cancer. But&#xD;
      for moderate-risk rectal cancer patients, whether neoadjuvant chemotherapy followed with&#xD;
      total mesorectal excision is adequate for local control is still unknown. The necessity of&#xD;
      preoperative radiotherapy for these patients needs further exploration.&#xD;
&#xD;
      This study is a single-arm, single-center, prospective, phase II clinical study. It is&#xD;
      designed to test the efficacy and safety of neoadjuvant chemotherapy for MRF-negative,&#xD;
      moderate-risk and initially resectable middle and low rectal cancer.&#xD;
&#xD;
      In this study, patients with MRI defined moderate-risk rectal cancer will receive a&#xD;
      three-month neoadjuvant chemotherapy based on Oxaliplatin combined with&#xD;
      Fluorouracil(CapeOX,SOX,mFOLFOX6,etc.) and Total mesorectal excision.&#xD;
&#xD;
      Primary Endpoint is pCR rate.Secondary endpoint concludes toxic reactions of neoadjuvant&#xD;
      chemotherapy, Incidence of surgical complications and three-year disease-free survival (DFS).&#xD;
&#xD;
      This study is designed to recruit 119 patients in all.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response rate</measure>
    <time_frame>30 days</time_frame>
    <description>the number of patients with pCR divided by the total number of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 year disease-free survival</measure>
    <time_frame>three years after the enrollment</time_frame>
    <description>cumulative rate of survival without cancer after 3 years follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical complication rate</measure>
    <time_frame>30 days after the operation</time_frame>
    <description>rate of patients who had surgical complications during the perioperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of neoadjuvant chemotherapy</measure>
    <time_frame>4 months</time_frame>
    <description>category and grade of adverse event during neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">119</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 130mg/m2 d1 and Capecitabine 1250mg/m2 bid1-14 or other fluorouracils, every 21 or 14 days for 2 to 4 cycles, and efficacy evaluation every 2 cycles;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin and capecitabine</intervention_name>
    <description>Patients receive 5-Fu and oxaliplatin based neoadjuvant chemotherapy for 3 months</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>antiemetics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Mesorectal Excision</intervention_name>
    <description>Patient receive total mesorectal excision after neoadjuvant chemotherapy</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>TME</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Age ≥18 years and ≤80 years&#xD;
&#xD;
               -  ECOG Performance status 0-1&#xD;
&#xD;
               -  Histologically confirmed diagnosis of adenocarcinoma of the rectum&#xD;
&#xD;
               -  The distance from down verge of tumor to anal-rectal junction (ARJ) ≤8cm based on&#xD;
                  MRI, or ≤12cm based on sigmoidoscopy;&#xD;
&#xD;
               -  Clinical Stage based on MRI&#xD;
&#xD;
                    1. mrMRF(-)&#xD;
&#xD;
                    2. T3c/T3d/T4a, anyN, or T3bN+&#xD;
&#xD;
               -  No evidence of distant metastases&#xD;
&#xD;
               -  No prior pelvic radiation therapy&#xD;
&#xD;
               -  No prior chemotherapy or surgery for rectal cancer&#xD;
&#xD;
               -  No active infections requiring systemic antibiotic treatment&#xD;
&#xD;
               -  ANC &gt; 1.5 cells/mm3, HGB &gt; 10.0 g/dL, PLT &gt; 100,000/mm3, total bilirubin ≤ 1.5 x&#xD;
                  ULN, AST≤ 3 x ULN, ALT ≤ 3 x ULN.&#xD;
&#xD;
               -  Patients must read, agree to, and sign a statement of Informed Consent prior to&#xD;
                  participation in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Recurrent rectal cancer&#xD;
&#xD;
               -  Primary unresectable rectal cancer. A tumor is considered unresectable when&#xD;
                  invading adjacent organs and an en-bloc resection will not achieve negative&#xD;
                  margins.&#xD;
&#xD;
               -  The pathological grade was Grade 4, i.e. mucus, signet ring or undifferentiated&#xD;
                  cancer.&#xD;
&#xD;
               -  Creatinine level greater than 1.5 times the upper limit of normal.&#xD;
&#xD;
               -  Patients who have received prior pelvic radiotherapy.&#xD;
&#xD;
               -  Patients who are unable to undergo an MRI.&#xD;
&#xD;
               -  Patients with a history of a prior malignancy within the past 5 years, except for&#xD;
                  adequately treated basal cell or squamous cell skin cancer.&#xD;
&#xD;
               -  Patients with a history of any arterial thrombotic event within the past 6&#xD;
                  months. This includes angina (stable or unstable), MI, TIA, or CVA.&#xD;
&#xD;
               -  Other Anticancer or Experimental Therapy.&#xD;
&#xD;
               -  Women who are pregnant or breast-feeding.&#xD;
&#xD;
               -  Patients with any other concurrent medical or psychiatric condition or disease&#xD;
                  which would make them inappropriate candidates for entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aiwen Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Cancer Hospital &amp; Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinyu Wang</last_name>
    <phone>+8618511834100</phone>
    <email>wxy_196@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aiwen Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Aiwen Wu</investigator_full_name>
    <investigator_title>chief, Unit III &amp; Ostomy Service, Gastrointestinal Cancer</investigator_title>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

